$413M Total Deal Value: Bausch Health Extends Tender Offer for DURECT with Major Milestone Package Bausch Health extends tender offer for DURECT Corp to Sept 10, offering $1.75/share upfront ($63M total) plus potential $350M in sales milestones. Deal completion requires majority shareholder approval.

#BHC #DRRX Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

www.stocktitan.net/news/BHC/bausch-health-a...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#SHEL, #FIS, #DRRX, #ATLX, #PPL

#OptionFlow #OptionsTrading #Trading

JUST IN: ( NASDAQ: #DRRX ) US Companies Moving the Markets, Evening edition <br>Tue, Jul 29, 2025 as of 4:00 pm ET

BREAKING NEWS: ( NASDAQ: #DRRX ) US Companies Moving the Markets, Morning edition <br>Tue, Jul 29, 2025 as of 10.00 am ET

DURECT Pushes Forward With Phase 3 Trial for Breakthrough Alcohol Hepatitis Treatment Following NEJM Evidence Validation DURECT plans pivotal Phase 3 trial for larsucosterol in alcohol-associated hepatitis, following NEJM Evidence publication. See timeline and financial details.

#DRRX DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/DRRX/durect-corpora...

DURECT Transforms Business: $17.5M Asset Sale, NEJM Evidence Validates Key Drug Program DURECT reduces annual losses by 71%, sells ALZET for $17.5M, and achieves NEJM Evidence publication for hepatitis drug. Phase 3 trial pending funding. Full analysis inside.

#DRRX DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/DRRX/durect-corpora...

DURECT Q4 Earnings Preview: Key Financial Results and Strategic Updates Coming March 26 DURECT Corporation reveals Q4 and 2024 performance on March 26. Join the investor call for latest financials and strategic insights into their epigenetic therapy pipeline.

#DRRX DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

www.stocktitan.net/news/DRRX/durect-corpora...

Revolutionary Liver Disease Drug Cuts Death Risk by More Than Half in US Patients Phase 2b trial results published in NEJM Evidence show DURECT's larsucosterol achieved 57% mortality reduction in US patients with severe alcohol-associated hepatitis. Phase 3 planned for 2025.

#DRRX DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence

www.stocktitan.net/news/DRRX/durect-corpora...

#DRRX DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million

www.stocktitan.net/news/DRRX/durect-corpora...

#DRRX DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/DRRX/durect-corpora...